Chordoma is an ultra-rare cancer derived from remnants of the embryonic notochord. With no currently approved agents and highly variable clinical behavior, chordoma presents unique challenges for research and treatment development. The rarity of the disease and low response rates make randomized studies particularly difficult.

The Chordoma Working Group aims to generate prospective data that can inform future clinical trial design, provide real-world evidence, and enable the creation of synthetic control arms to reduce the number of patients required for randomization in future studies.

Our Objectives
This working group is developing tools and frameworks to support chordoma research within and beyond the PUSH Platform. The team is currently defining case report forms (CRFs) for both retrospective and prospective data collection and is contributing to the design of a potential external platform trial in which control arm data may be supplemented by real-world evidence collected through PUSH.

Our Core Initiatives

• Develop CRFs for prospective data collection and ensure alignment across retrospective and prospective studies.


• Design protocols that integrate PUSH data into future chordoma trials.


• Support collaborative study design to accelerate clinical insights and reduce barriers to trial participation.